Danerius, LLC
Alan W. Dunton, M.D., Principal and Founder
Alan W. Dunton, M.D. is the founder of Danerius, LLC. He is a seasoned, globally-experienced pharmaceutical/biotechnology industry executive with over 30 years of experience. His career has ranged from responsibility for overall leadership of large pharma R&D organizations to private biotechnology companies focused on Rx and OTC drug development, as well as devices. His in-depth formal training in Internal Medicine and Clinical Pharmacology facilitated a unique understanding of disease and health and the role of therapeutic modalities. Combining this training with his extensive company leadership and drug development experience, he is uniquely positioned to offer advice across all aspects of the pharmaceutical/ biotechnology industry on a local or global scale.

Dr. Dunton has held significant senior positions in major pharmaceutical companies. He has been directly responsible for or has overseen the successful development/original/line extension approvals of Levaquin®, Regranex®, Aleve®, Procrit/EPREX®, Sporanox®, Reminyl® and Risperdal®, to name a few. Dr. Dunton also served as Senior Vice President of R&D at Purdue Pharma and President and Chief Executive Officer of a small biotech firm, Panacos Pharmaceuticals, Inc., a company focused on treatment resistant HIV therapeutics. Previously, he was the President and CEO of Metaphore Pharmaceuticals, which focused on anti-inflammatory and analgesic products. Dr. Dunton was a senior executive in various capacities in the Pharmaceuticals Group of Johnson & Johnson including President and Managing Director of The Janssen Research Foundation. He also served as Group Vice President of global clinical research and development of Janssen as well as the R.W. Johnson Pharmaceutical Research Institute, also a Johnson & Johnson company. Dr. Dunton has also held positions in clinical research and development at Syntex Corporation, CIBA-GEIGY Corporation and Hoffmann La Roche Inc. 

Dr. Dunton is currently serving as a Director of the following companies: Oragenics, Inc. (OGEN), Palatin Technologies Inc. (PTN), CorMedix (CRMD), Recce Pharmaceuticals (ASX:RCE), Regeneus Ltd. (ASX:RGS) and Cytogel Pharma, a privately-held company. He has also served as Executive Director or Director of several private companies including ActivBiotics, VWR, Metaphore Pharmaceuticals, as well as a Director of public companies which included Vicuron, Adams Respiratory Therapeutics, Emisphere Technologies, Panacos Pharmaceuticals, MediciNova, Inc., EpiCept Corporation, Targacept, Inc. and Bionomics.

Dr. Dunton holds a M.D. degree from New York University School of Medicine, where he completed his residency in internal medicine. He also was a Fellow in Clinical Pharmacology at the New York Hospital/Cornell University Medical Center